Swiss Life Asset Management Ltd Acquires 3,789 Shares of Waters Corporation $WAT

Swiss Life Asset Management Ltd boosted its stake in shares of Waters Corporation (NYSE:WAT) by 28.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 17,218 shares of the medical instruments supplier’s stock after buying an additional 3,789 shares during the period. Swiss Life Asset Management Ltd’s holdings in Waters were worth $5,162,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of WAT. Brighton Jones LLC raised its holdings in shares of Waters by 112.9% during the fourth quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock worth $471,000 after acquiring an additional 673 shares during the period. Integrated Wealth Concepts LLC boosted its stake in Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after purchasing an additional 30 shares during the period. Goldman Sachs Group Inc. increased its holdings in Waters by 3.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock worth $73,733,000 after purchasing an additional 6,976 shares in the last quarter. Empowered Funds LLC increased its holdings in Waters by 16.6% during the 1st quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock worth $415,000 after purchasing an additional 160 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Waters in the second quarter valued at about $232,000. Institutional investors own 94.01% of the company’s stock.

Waters Stock Performance

Shares of WAT stock opened at $299.48 on Friday. The company has a fifty day moving average price of $342.55 and a two-hundred day moving average price of $351.11. Waters Corporation has a one year low of $275.05 and a one year high of $414.15. The stock has a market cap of $29.38 billion, a P/E ratio of 27.81, a P/E/G ratio of 2.06 and a beta of 1.20. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.73 and a quick ratio of 1.27.

Waters (NYSE:WAT) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share for the quarter, topping the consensus estimate of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The company had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. During the same period in the previous year, the business earned $4.10 EPS. Waters’s revenue for the quarter was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. As a group, equities analysts predict that Waters Corporation will post 12.86 EPS for the current year.

Insider Activity

In other Waters news, Director Wei Jiang bought 500 shares of Waters stock in a transaction dated Monday, March 16th. The stock was bought at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the purchase, the director owned 3,441 shares of the company’s stock, valued at $996,031.86. The trade was a 17.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.63% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on WAT. Citigroup initiated coverage on Waters in a research report on Tuesday, February 10th. They issued a “buy” rating and a $425.00 target price on the stock. Barclays started coverage on shares of Waters in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $400.00 price objective on the stock. Bank of America decreased their target price on shares of Waters from $410.00 to $350.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Waters from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $393.84.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.